Logo Medical Science Monitor

Call: +1.631.470.9640
Closed: National Holiday

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 September 1996

Assessment of fusafungine efficacy and tolerance in upper respiratory infections

Bolesław Samoliński, Janusz Kamiński, Marcin Kargul

Med Sci Monit 1996; 2(5): PI650-656 :: ID: 500092


Assessment of clinical efficacy of fusafungine, a preparation combining properties of antibiotic and antiinflammatory agents, was carried out on a group of 1325 patients with symptoms of acute inflammation of the nasal mucosa, sinuses, pharynx, palatine tonsils and bronchi. Patients were subjected to a seven-day treatment and evaluation. Fusafungine effects on particular symptoms and clinical efficacy were assessed by both patients and their physicians in charge. The study was done as an open multicentre trial. In 35% of patients antiinflammatory nonsteroid drugs were administered; 18% of patients received general antibiotics (50% of those were given in bronchitis). Statistically significant differences in remission were noted in the majority of conditions as early as the first 24 hours (p<0.01). The best results were observed in acute palatine tonsillitis (except for streptococcal pharyngitis) and acute rhinitis and pharyngitis (very good and good results represented by 92% and 93% respectively). In bronchitis and sinusitis the effects were milder (77% and 78% respectively). Sore throat, hoarseness and nasal congestion showed the most effective (over 40%) and quickest (50% symptom reduction at 4 days) remission. The poorest results were observed in remission of cough and rhinorrhoea (less than 35% improvement, 50% symptom reduction as late as at 7 days). In general the best results were noted in 39%, good in 48% and poor in 13% of the patients. A poor response was observed in 4% of cases. Adverse symptoms were reported by 8% of patients and proved to be local.

Keywords: Sinusitis, Pharyngitis, Laryngitis, Bronchitis, antibiotic therapy, fusafungine

Add Comment 0 Comments

429 0


01 May 2023 : Editorial  

Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.940911

Med Sci Monit 2023; 29:e940911

In Press

28 May 2023 : Database Analysis  

Scientometric and Visualized Analysis of Intravoxel Incoherent Motion Magnetic Resonance Imaging: 1988-2021

Med Sci Monit In Press; DOI: 10.12659/MSM.938715  

25 May 2023 : Database Analysis  

The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.940904  

25 May 2023 : Review article  

A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drug...

Med Sci Monit In Press; DOI: 10.12659/MSM.940635  

25 May 2023 : Clinical Research  

Periapical Lesions and Missed Canals in Endodontically Treated Teeth: A Cone-Beam Computed Tomographic Stud...

Med Sci Monit In Press; DOI: 10.12659/MSM.940533  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750